The estimated Net Worth of William Michael Kavanaugh is at least $933 millier dollars as of 8 December 2017. William Kavanaugh owns over 5,130 units of Five Prime Therapeutics Inc stock worth over $933,303 and over the last 10 years William sold FPRX stock worth over $0.
Sign up
William Kavanaugh FPRX stock SEC Form 4 insiders trading
William has made over 4 trades of the Five Prime Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently William exercised 5,130 units of FPRX stock worth $8,054 on 8 December 2017.
The largest trade William's ever made was exercising 48,368 units of Five Prime Therapeutics Inc stock on 4 October 2017 worth over $216,205. On average, William trades about 5,186 units every 73 days since 2014. As of 8 December 2017 William still owns at least 19,047 units of Five Prime Therapeutics Inc stock.
You can see the complete history of William Kavanaugh stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's William Kavanaugh's mailing address?
William's mailing address filed with the SEC is C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Five Prime Therapeutics Inc
Over the last 11 years, insiders at Five Prime Therapeutics Inc have traded over $158,392,438 worth of Five Prime Therapeutics Inc stock and bought 4,750,507 units worth $20,970,721 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... et Capital Partners Gp, L.L.C..... On average, Five Prime Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $6,730,346. The most recent stock trade was executed by Francis Willard Sarena on 11 December 2020, trading 22,000 units of FPRX stock currently worth $1,078,000.
What does Five Prime Therapeutics Inc's logo look like?
Complete history of William Kavanaugh stock trades at CytomX Therapeutics Inc et Five Prime Therapeutics Inc
Five Prime Therapeutics Inc executives and stock owners
Five Prime Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Peder Jensen,
Director -
Sheila Gujrathi,
Director -
Mark Mcdade,
Director -
Kapil Dhingra,
Director -
Fred E Cohen,
Director -
Garry A Nicholson,
Director -
Franklin M Berger,
Director -
Robert Steven Sikorski,
SVP and Chief Medical Officer -
Luis Borges,
SVP, Research -
Kevin Paul Baker,
SVP, Development Sciences -
Marc Belsky,
SVP and CFO -
R Lee Douglas,
Director -
Francis Willard Sarena,
Chief Strategy Officer -
Aron Marc Knickerbocker,
President & CEO -
David V Smith,
Executive Vice President & CFO -
Lewis T Williams,
Director -
David White,
See Remarks -
Carol Schafer,
Director -
Partners L P/Ilbiotechnolog...,
-
Bryan Irving,
EVP, Chief Scientific Officer -
Capital Partners Gp, L.L.C....,
-
Julie Hambleton,
SVP & Chief Medical Officer -
William Michael Kavanaugh,
SVP & Chief Scientific Officer -
Brian G Atwood,
Director -
Lori Lyons Williams,
Director -
Helen Louise Collins,
EVP and Chief Medical Officer -
William R Ringo,
Director -
Thomas Civik,
President and CEO -
Partners L P/Ilbiotechnolog...,